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ABSTRACT
Current vascular-targeted therapies in colorectal cancer (CRC) have shown limited 
benefit. The lack of novel, specific treatment in CRC has been hampered by a dearth 
of specific endothelial markers. Microarray comparison of endothelial gene expression 
in patient-matched CRC and normal colon identified a panel of putative colorectal 
tumour endothelial markers. Of these the glutamate dependent NMDA receptor GRIN2D 
emerged as the most interesting target. GRIN2D expression was shown to be specific to 
colorectal cancer vessels by RTqPCR and IHC analysis. Its expression was additionally 
shown be predictive of improved survival in CRC. Targeted knockdown studies in vitro 
demonstrated a role for GRIN2D in endothelial function and angiogenesis. This effect 
was also shown in vivo as vaccination against the extracellular region of GRIN2D 
resulted in reduced vascularisation in the subcutaneous sponge angiogenesis assay. 
The utility of immunologically targeting GRIN2D in CRC was demonstrated by the 
vaccination approach inhibiting murine CRC tumour growth and vascularisation. 
GRIN2D represents a promising target for the future treatment of CRC.
INTRODUCTION
Colorectal cancer is the third most common cancer 
globally, making up about 10% of all malignant diagnoses 
[1]. There are over 1.4 million new cases annually, 65% 
of which are found in developed countries, with 695,000 
deaths from the disease. Early stage colorectal cancer, 
confined to the wall of the colon, is usually curable with 
surgery. More advanced disease, making up 50% of cases 
in the UK, has a poorer prognosis, and often requires the 
addition of adjuvant therapies such as chemotherapy [1].
The five-year survival rate in developed countries 
is around 65%, however, this drops to below 10% with 
metastatic disease [2]. Curative treatment heavily relies 
upon the achievement of a histologically clear resection 
margin at surgery [3, 4] and although 80% of CRC 
resections do achieve this, 50% will relapse to metastatic 
disease, due to the presence of micro-metastases present at 
the time of resection [2, 5]. Improvements in treatment and 
prevention of metastatic disease, are of vital importance to 
achieve better outcomes in CRC.
Adjuvant therapeutic agents have been in established 
use in the treatment of colorectal cancer (CRC) for over 50 
years [6], but despite introduction of new chemotherapeutic 
agents, and the introduction of monoclonal antibodies, 
presentation with macroscopic or microscopic metastatic 
disease still carries a poor prognosis [7]. This is partly because 
primary colorectal cancer remains a difficult target for immune 
therapies [8], with no currently licenced immunotherapies 
for the Dukes A-C disease. Cetuximab, bevacizumab, and a 
third monoclonal antibody, panitumumab, are also currently 
licenced for use in the treatment of advanced CRC, although 
evidence of benefit is limited, with response rates below 5% 
when used as a monotherapy [9]. Targeting of the vasculature 
of CRC has been shown to be a mechanism of interest for 
novel therapies [10], with anti-angiogenic agents already 
licensed for advanced disease. However, vascular targeting in 
the form of a targeted specific immunotherapy, or vaccination, 
in CRC has not been previously described.
The development of antigen-specific immunotherapies 
relies upon identification of a specific, over-expressed antigen 
in the malignancy of interest [11]. Previous work from our 
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group has identified both ROBO4 [12] and CLEC14A [13] 
as endothelial specific targets in human malignancy. The 
breaking of immune self tolerance to ROBO4, through 
vaccination, has been shown to result in decreased tumour 
growth through anti-angiogenic effects in a subcutaneous 
murine Lewis Lung Carcinoma model [14].
This article describes the identification of 
GRIN2D (also known as NMDAR2D, NR2D, GluN2D), 
a subunit of a glutamate dependent, ionotropic NMDA 
receptor, and facilitator of cellular calcium influx, 
previously found in neuronal tissues, as a putative 
vascular endothelial target in CRC.
RESULTS
In order to identify novel tumour vascular markers 
in CRC, comparative analysis of microarray data of 
four endothelial isolates from colorectal cancer and 
patient matched healthy colon tissue was conducted. The 
generation of the endothelial isolates and raw microarray 
data is described in Wragg et al., 2015 [15].
A number of known tumour associated angiogenic 
genes were identified by this analysis (Table 1), including 
interleukin 8, angiopoietin 2 and lysyl oxidase like 2, 
validating the approach as a method for identifying genes 
enriched on tumour endothelium. This analysis additionally 
identified a host of collagens (Supplementary Table S1) 
and matrix metallopeptidases (Supplementary Table S2), 
key components of active extracellular matrix remodelling, 
important for endothelial migration and angiogenesis within 
the tissue. This data collectively implies a pattern of active 
angiogenesis occurring within the tumour, outstripping that 
of the surrounding healthy colon tissue.
Selection of genes of interest
In order to identify potential endothelial markers 
in colorectal cancer, which can then be used to target 
therapeutics to the tumour vascular bed, a short list 
of genes of interest was generated (Table 2). This list 
detailed genes at least 5 times enriched on colorectal 
cancer vessels, with a p-value <0.05 and with considerable 
evidence of trans-plasma-membrane expression. This was 
done to ensure that selected genes had both considerable 
differential expression, but were also directly targetable 
from the bloodstream. This would simplify the mode of 
delivery of any potential therapeutics targeted against 
them. A literature review was undertaken on all targets, 
and those with prior published evidence in the context 
of colorectal cancer endothelium were excluded from 
further study. This left eight candidate targets: stimulated 
by retinoic acid gene 6 (STRA6); glutamate receptor, 
ionotropic, N-methyl D-aspartate 2D (GRIN2D); 
fibronectin type III domain containing 1 (FNDC1); G 
protein-coupled receptor 4 (GPR4); regulator of G-protein 
signalling 5 (RGS5); transglutaminase 2 (TGM2); 
potassium inwardly-rectifying channel, subfamily J, 
member 8 (KCNJ8) and olfactory receptor, family 51, 
subfamily E, member 1 (OR51E1).
Validation of genes of interest
RTqPCR was conducted on the eight selected 
candidate targets, in order to compare gene expression in 
colorectal cancer endothelial cells (EC) and healthy colon 
EC (n=8 for each) (Figure 1A). Gene expression was 
normalised to both flotillin-2 (per cell expression level) 
and PECAM-1 (per endothelial cell expression level) in 
order to assess the level of enrichment of the target in 
the cancer endothelium (Table 3). Additionally, target 
gene expression level in the cancer EC was compared to 
flotillin-2 expression, in order to ensure that genes were 
expressed at a high enough level to be of interest (Table 3). 
This investigation identified GRIN2D alone as having 
sufficient cancer enrichment and expression, to be taken 
forward for further investigation.
Differential expression of GRIN2D was further 
validated on the protein level by immunohistochemistry 
(IHC) on formalin fixed paraffin embedded sections 
(Figure 1B). Sections of colorectal cancer and 
healthy colon were stained for PECAM-1 (a marker 
of endothelium) and GRIN2D by IHC. This analysis 
determined that the vessels in colorectal cancer stain 
strongly for GRIN2D, however, vessels in the healthy 
colon, marked by PECAM-1 staining do not stain for 
GRIN2D (Figure 1B). Additionally GRIN2D IHC staining 
was assessed by multi-organ tissue array analysis, in 
order to determine its global tumour and healthy tissue 
expression profile (Figure 1C). This involved staining 
10 samples each of 12 different tumour and matched 
healthy tissue sample for GRIN2D. The analysis identified 
GRIN2D to be positively expressed on the vessels of 
40% of colorectal cancers, but only 10% of healthy 
colon samples. It was additionally expressed on a range 
of cancer and healthy tissues to a lesser extent. The fact 
that GRIN2D is expressed to a greater extent in cancerous 
tissues and in colon cancer in particular, is encouraging 
in that it suggests a potential for vessel specific targeting, 
but normal tissue expression would necessitate careful 
monitoring for tissue toxicity.
In order to investigate whether the expression of 
GRIN2D has any prognostic value in colorectal cancer, 90 
colorectal tumours were stained for GRIN2D (Figure 1D). 
Key clinical data for this cohort is shown in Supplementary 
Table S3. The survival of patients with tumours positive or 
negative for GRIN2D staining was compared by log-ranks 
statistical analysis (Figure 1D). This analysis determined 
that patients with positive vascular GRIN2D expression 
survived for longer than those without, though not to a 
significant level (p=0.053).
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Table 1: Transmembrane genes greater than 5 fold enriched in colorectal cancer vessels
Gene ID Gene Symbol GeneBank 
accession no.
LogFC P-value
EGF-like-domain, multiple 6 EGFL6 NM_001167890 4.86 0.00
thrombospondin 2 THBS2 NM_003247 4.26 0.00
fibroblast activation protein, alpha FAP NM_004460 4.11 0.00
leucine zipper, putative tumor suppressor 1 LZTS1 NM_021020 4.03 0.00
Thy-1 cell surface antigen THY1 NM_006288 3.87 0.00
Fc fragment of IgG, low affinity IIIa, receptor (CD16a) FCGR3A NM_000569 3.58 0.00
interleukin 6 (interferon, beta 2) IL6 NM_000600 3.40 0.00
stimulated by retinoic acid gene 6 homolog (mouse) STRA6 NM_001199042 3.15 0.00
plexin domain containing 1 PLXDC1 NM_020405 3.12 0.01
potassium inwardly-rectifying channel, subfamily J, 
member 8 KCNJ8 NM_004982 2.97 0.00
placental growth factor PGF NM_002632 2.92 0.01
pyrimidinergic receptor P2Y, G-protein coupled, 6 P2RY6 NM_176798 2.87 0.00
glutamate receptor, ionotropic, N-methyl D-aspartate 2D GRIN2D NM_000836 2.83 0.01
platelet-derived growth factor receptor, beta polypeptide PDGFRB NM_002609 2.82 0.00
frizzled family receptor 10 FZD10 NM_007197 2.81 0.00
tribbles homolog 3 (Drosophila) TRIB3 NM_021158 2.81 0.01
regulator of G-protein signaling 5 RGS5 NM_003617 2.79 0.00
claudin 2 CLDN2 NM_001171092 2.75 0.02
wingless-type MMTV integration site family member 2 WNT2 NM_003391 2.75 0.00
uncharacterized LOC541471 LOC541471 NR_015395 2.73 0.01
leukocyte immunoglobulin-like receptor, subfamily B, 
member 4 LILRB4 BC026309 2.71 0.01
solute carrier family 4, sodium borate transporter, 
member 11 SLC4A11 NM_032034 2.67 0.01
macrophage receptor with collagenous structure MARCO NM_006770 2.67 0.01
vasorin VASN NM_138440 2.66 0.00
transglutaminase 2 TGM2 NM_198951 2.60 0.00
sulfatase 1 SULF1 NM_015170 2.58 0.02
leucine rich repeat and Ig domain containing 1 LINGO1 NM_032808 2.57 0.00
SLAM family member 8 SLAMF8 NM_020125 2.52 0.03
olfactory receptor, family 51, subfamily E, member 1 OR51E1 NM_152430 2.50 0.00
gap junction protein, alpha 4, 37kDa GJA4 NM_002060 2.50 0.00
interleukin 13 receptor, alpha 2 IL13RA2 NM_000640 2.45 0.02
regulator of G-protein signaling 16 RGS16 NM_002928 2.44 0.01
fibronectin type III domain containing 1 FNDC1 NM_032532 2.39 0.02
notch 3 NOTCH3 NM_000435 2.34 0.00
ArfGAP with dual PH domains 2 ADAP2 NM_018404 2.87 0.00
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In vitro effects of GRIN2D knockdown on 
angiogenesis
In order to investigate the functional role GRIN2D 
plays in tumour endothelium, human umbilical cord 
vein endothelial cells (HUVEC) were transfected with 
small interfering RNA (siRNA) duplexes corresponding 
to GRIN2D, to selectively silence its expression. Gene 
silencing and protein depletion was confirmed by RTqPCR 
and western blot analysis (Supplementary Figure S1). This 
revealed a 60-70% reduction in GRIN2D expression in the 
presence of GRIN2D siRNA duplexes.
The cell-to-cell communication required for 
endothelial cells to differentiate into vascular tubes is vitally 
important for their healthy function. To assess the impact that 
the partial loss of GRIN2D expression has on this process, 
a matrigel tube-forming assay was performed. By assessing 
the complexity of network endothelial cells are able to form 
when grown on the matrigel, their functionality can be 
determined. This is done by quantifying the number of nodes 
(network intersections) and sprouts per node, in this model 
of endothelial capillary formation. The capillary networks 
formed by endothelial cells from three HUVEC cords 
showed significant reduction in both the number of nodes 
(p<0.001) and sprouts per node (p<0.001) when treated with 
either GRIN2D siRNA duplex, compared to the scrambled 
control duplex, suggesting GRIN2D plays some role in the 
endothelial capillary tube formation (Figure 2A–2C).
The rate of endothelial cell migration is an important 
indicator of functionality. To determine the effect GRIN2D 
knockdown has on endothelial migration, scratch wound 
assays were performed. In this assay, scratches are scored 
through a confluent monolayer of endothelial cells. 
Three scratches are scored from top to bottom and three 
from left to right, generating nine intersecting sites into 
which endothelial cells will migrate, closing the scratch. 
By determining the percentage of the scratch wound 
still open at the point where the control duplex is 90% 
closed, the rate of endothelial migration can be compared. 
The percentage scratch wound closure was significantly 
reduced by GRIN2D knockdown by both duplexes, when 
compared to the scrambled control (p<0.001), suggesting 
that GRIN2D also plays a significant role in endothelial 
migration (Figure 2D&2E).
Table 2: Known tumour associated or angiogenic genes enriched in colorectal cancer vessels
Gene ID Gene Symbol GeneBank 
accession no.
LogFC P-value
interleukin 8 IL8 NM_000584 3.42 0.00
angiopoietin 2 ANGPT2 NM_001147 3.40 0.00
plexin domain containing 1 PLXDC1 NM_020405 3.12 0.01
lysyl oxidase-like 2 LOXL2 NM_002318 3.11 0.01
hairy/enhancer-of-split related with YRPW 
motif-like
HEYL NM_014571 3.01 0.00
placental growth factor PGF NM_002632 2.92 0.01
platelet-derived growth factor receptor, beta 
polypeptide PDGFRB NM_002609 2.82 0.00
endothelial cell-specific molecule 1 ESM1 NM_007036 2.63 0.00
CD86 molecule CD86 NM_006889 2.42 0.05
apelin APLN NM_017413 1.98 0.00
insulin-like growth factor binding protein 7 IGFBP7 NM_001553 1.93 0.01
angiopoietin-like 2 ANGPTL2 NM_012098 1.65 0.09
major histocompatibility complex, class II, 
DR alpha HLA-DRA NM_019111 1.65 0.05
tenascin C TNC NM_002160 1.42 0.12
secreted protein, acidic, cysteine-rich 
(osteonectin) SPARC NM_003118 1.39 0.13
neuropilin 1 NRP1 NM_001024629 1.23 0.08
lysyl oxidase LOX NM_002317 1.20 0.21
anthrax toxin receptor 1 ANTXR1 NM_053034 1.01 0.20
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Figure 1: GRIN2D is a specific marker of tumour vasculature in colorectal cancer. A. quantitative real-time analysis of relative candidate 
target gene levels in endothelium isolated from malignant and healthy tissue. Gene expression levels were normalised to flotillin-2. Average gene 
expression ± SEM (n=8, Mann-Whitney U, ***p<0.0001, **p<0.001). B. representative images of PECAM-1 and GRIN2D staining in healthy colon 
and colorectal cancer (scale bar = 50 μm). C. multi-organ tissue array analysis of GRIN2D expression, showing the frequency of positive GRIN2D 
vascular staining. D. representative images of positive and negative GRIN2D staining in CRC by IHC (scale bar = 50 μm) and Kaplan-Meier analysis 
of survival in CRC with (blue) or without (green) GRIN2D vascular expression. Statistical analysis = Log-ranks test, P and N-numbers shown.
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Endothelial migration takes many forms, and the 
scratch wound assay cannot accurately assess this alone. 
The transfilter assay tests the ability of the endothelial cell 
to transmigrate through a filter, stimulated by a growth 
factor and mitogen concentration gradient. In order to 
assess the effect the loss of GRIN2D has on transmigration, 
this assay was performed. The experimental set up is 
outlined in Figure 2F, and is summarised in the methods 
section.
The percentage of cells that have migrated across 
the membrane was significantly reduced by GRIN2D 
knockdown by both duplexes when compared to the 
scrambled control (p<0.001), suggesting that GRIN2D 
plays a role in endothelial transmigration (Figure 2G).
Designing a GRIN2D-based tumour vaccine
As the loss of GRIN2D was found to have anti-
angiogenic effects in vitro, it was investigated as a 
potential target for anti-angiogenic vaccination. To 
stimulate host immune response against endogenous 
GRIN2D, a unique, extracellular epitope was identified. 
GRIN2D is an ionotropic NMDA receptor subunit, 
and as such has been predicted to have an intracellular 
C-terminus, and an extracellular N-terminus [16]. 
Between these termini, there are predicted to be four 
transmembrane regions, the second of which forms the 
ion channel in conjunction with three other subunits. 
This has been described as a putative structure for the 
NR2 subunits, with analogous structures in the AMPA 
glutamate receptor confirmed by fluorescence-detection 
size-exclusion chromatography [17]. The FASTA 
sequence of murine GRIN2D (mGRIN2D) was aligned 
with all other GRIN2 subgroup members using CLUSTAL 
Omega software (EMBL-EBI, Cambridge, UK), and 
areas of unique sequence cross-referenced with predicted 
extracellular regions. A sequence of 78 amino acids unique 
to mGRIN2D was identified (Supplementary Figure S2), 
and underwent comparative sequence analysis using the 
Protein Basic Local Alignment Search Tool (BLASTp) 
tool (NCBI, Bethesda, MD, USA) to ensure there was 
no significant sequence homology with any other murine 
protein, thereby decreasing the likelihood of off-target 
effects of any future targeted therapy.
The selected GRIN2D peptide sequence was 
generated as a fusion protein with the Fc fragment of 
human IgG1 using the pIgG vector expression system in 
HEK293T-cells. The Fc tag enables interaction with the Fc 
receptors of circulating immune cells, thereby increasing 
the immune response against the fusion partner [18], in 
this case GRIN2D. The resultant GRIN2D-Fc protein 
was affinity purified using a protein A column. Protein 
purity was confirmed by SDS-page gel electrophoresis 
(Supplementary Figure S2).
Vaccination against GRIN2D impairs 
angiogenesis and tumour growth
To investigate the in vivo effects of targeting 
GRIN2D by vaccination, mGRIN2D-Fc fusion protein 
was administered in emulsion with Freund’s adjuvant to 
separate groups of six mice, with Fc alone in Freund’s 
administered to the control group. Utilising this approach, 
mice received 50 μg of mGRIN2D-Fc fusion protein 
subcutaneously with 100 μl of Freund’s adjuvant at day 
0 and day 14, with a terminal cardiac bleed taken at day 
28 (Supplementary Figure S3) . ELISA was utilised to 
quantify the specific immune response to GRIN2D, and 
to differentiate the immunoglobulin isotype involved in 
the response (Figure 3A&3B). This analysis confirmed 
a specific immune response to GRIN2D, predominated 
by IgG1 and IgG2b, indicating a Th-2 T-cell response, 
consistent with immunisation [19]. Importantly, there was 
no evidence of a significant difference between groups in 
antibody response to the Fc component of the vaccine, 
when measured by ELISA (p=0.379, Mann Whitney).
Table 3: Selection of genes of interest for further investigation and validation based on gene enrichment and 
expression level in the tumour endothelial isolates
Flotillin-2 vs. target 
fold expression 
change
PECAM vs. target 
fold expression 
change
Expression level 
relative to flotillin-2 
(%)
Selected genes
STRA6 30.7 5.1 10.6
GRIN2D 35.4 15.8 35.0 GRIN2D
FNDC1 20.5 2.4 16.9
GPR4 22.7 8.8 17.3
RGS5 3.7 1.0 109.1
TGM2 1.7 0.5 841.7
KCNJ8 7.5 6.25 4.4
OR51E1 7.1 4.0 8.8
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Figure 2: Loss of GRIN2D impairs endothelial function in in vitro angiogenesis assays. GRIN2D was knocked down by 
transfection of two siRNA duplexes into 3 separate HUVEC isolates. A–C, the cells were plated on matrigel and endothelial tube formation 
and integrity observed over 16 hours. A, representative images of tube formation in each condition. B, the average number of nodes per 
field of view ± SEM. C, the average number of sprouts per node ± SEM (n=6 per condition [3] and isolate [3]). D–E. HUVEC were plated 
and allowed to grow to confluence. The monolayer was scratched and wound closure observed at nine scratch intersections over time. D, 
representative images of wound closure from initial scratch to end-stage. E, quantification of percentage wound closure over the time course 
of the experiment ± SEM (n=9 per condition [3] and isolate [3]). F–G. HUVEC were subjected to the transfilter (modified Boyden chamber) 
assay, the set up of which is shown in F. G, quantification of the average percentage of endothelial cells that have migrated through the filter, 
after 16 hours, per field of view ± SEM (n=6 per condition [3] and isolate [3]). Statistical analysis for all, Mann-Whitney U, ***p<0.0001.
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Figure 3: The physiological effects of GRIN2D-Fc vaccination. A-B. quantitation of immune response to vaccination with GRIN2D-
Fc fusion protein by ELISA, showing A, overall response and B, IgG specific response. Vaccinated mice had sponges introduced into their 
flank and angiogenesis was stimulated into the sponge with FGF infusions. C. representative images of macroscopic vascular invasion into 
the sponge in the treated and untreated groups. A mask was generated in image J  [54] for each sponge and the percentage sponge invasion 
quantified, D, E. representative H&E images of subcutaneous sponge morphology. F. quantitation from the H&E images of sponge vessel 
density. Statistical analysis for all, Mann-Whitney U, ***P<0.0001, **P<0.001. 6 sponges in each group, 5 microscopic fields per sponge.
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The effects of targeting GRIN2D on in vivo 
angiogenesis was investigated using the subcutaneous 
sponge assay. Following vaccination with mGRIN2D-Fc, 
sponges were paraffin embedded, sectioned and stained with 
haematoxylin and eosin (H&E). Random fields were assessed 
for blood vessel count. A significant decrease in both sponge 
invasion (p=0.0026) and vessel density (p<0.0001) was 
observed compared to controls (Figure 3C–3F), implicating 
GRIN2D in the process of angiogenesis in vivo.
This vaccination approach was extended to target 
tumour vessels and angiogenesis in a murine model of 
CRC (CT26). Tumours grown in mice vaccinated against 
GRIN2D were found to display a significant decrease in 
tumour growth by calliper measurement (p=0.004, Mann-
Whitney) (Figure 4A). This was corroborated by analysis 
of excised tumour appearance and weight (p=0.0274) 
(Figure 4B&4C). Interestingly, RTqPCR quantification of 
GRIN2D expression within the endothelial compartment 
of the excised tumours endothelial cells demonstrated a 
5.5-fold upregulation of expression within the mGRIN2D-
Fc treated group compared to controls, when adjusted 
for endothelial isolation efficiency (p=0.0069, Mann-
Whitney). Vascular density was quantified in H&E sections 
of excised CT26-Luc tumours, indicating a significant 
decrease in the numbers of vessels per field in five random 
microscopic fields per tumour (mean 78 vs. 62 vessels per 
field, p=0.0367, Mann Whitney) (Figure 4D). This result 
demonstrates the utility of GRIN2D vaccination as an anti-
angiogenic approach to treat colorectal cancer.
DISCUSSION
Microarray transcriptomic analysis on freshly 
isolated endothelium from colorectal cancer and matched 
healthy colon has identified a panel of putative colorectal 
tumour endothelial markers. Of these the glutamate 
receptor GRIN2D emerged as the most interesting target. 
GRIN2D was shown to have vessel-restricted expression 
in colorectal cancer by RTqPCR and IHC analysis. Multi-
organ tissue array analysis identified GRIN2D to be 
predominantly expressed in tumour tissue, particularly 
in colorectal malignancies, where its expression was 
shown to be associated with increased survival. In vitro 
analysis of GRIN2D’s endothelial function showed it to 
be important in endothelial migration and capillary tube 
formation in matrigel. In vivo analysis showed GRIN2D 
vaccination to be an effective approach to inhibit both 
physiological and tumour-associated angiogenesis.
GRIN2D is primarily studied as a neuronal 
ionotropic glutamate receptor, involved in long-term 
potentiation, and plays a role in certain types of learning 
and memory. GRIN2D is a component of the N-methyl-D 
aspartate (NMDA) receptor calcium channels, which are 
heterotetramers formed from a combination of GRIN1 
and either GRIN2 or GRIN3 subunits [20]. It is widely 
expressed within the brain, in particular the developing 
diencephalon, however, selective knockout mice develop 
normally both pre- and post-natally, with normal mating 
behaviour [21]. No observed effect is described in motor 
activity or anxiety tests among selective knockout mice, 
however, due to the loss of function of certain NMDA 
receptors, mice showed altered emotional behaviour in 
forced swimming and light/dark box stress tests [22]. This 
led to the suggestion of its role in the glutaminergic theory 
of schizophrenia, interest in which has been a focus of much 
research, reviewed in Moghaddam and Javitt, 2012 [23].
Neuronal and vascular cells share an embryonic stem 
cell lineage, leading to considerable cross-expression of 
endothelial and neuronal genes and many similarities in the 
processes that govern the modelling of vascular and neuronal 
architecture [24]. With this in mind it is unsurprising that a 
traditionally neuronal glutamate receptor GRIN2D should be 
found to be expressed on endothelial cells.
GRIN2D’s identity as a component of a calcium 
channel could be responsible for its observed role in 
angiogenesis. VEGF, a potent stimulatory growth factor of 
angiogenesis, promotes endothelial migration, proliferation 
and capillary formation in part via VEGF-mediated calcium 
influx [25]. Increased intracellular calcium concentration, 
observed or induced by arachidonic acid, has been reported 
to promote endothelial migration and tube formation in 
angiogenesis assays [26, 27]. Loss of GRIN2D by siRNA 
knockdown results in reduced endothelial migration, tube 
formation and transmigration, which could be in part due to 
reduced calcium influx into the endothelial cells, curtailing 
the efficiency of growth factor mediated endothelial 
function, although this theory requires further investigation.
The functioning of GRIN2D in neuronal calcium 
channels is distinct from that of other NMDA receptor 
components, in that it promotes calcium influx over 
an extended period, mediating its role in long term 
potentiation [28, 29]. It is therefore easy to see how, 
by offering long-term calcium influx, the promotion 
of GRIN2D containing calcium channels in tumour 
endothelium could offer a survival advantage and even 
prime endothelial cells to respond to pro-angiogenic 
growth factor signalling within the tumour. Calcium 
flux and metabolism has been suggested as a target for 
anti-angiogenic therapy [30] and targeted inhibition of 
GRIN2D could be a potential method for achieving this.
Multiple links have been described between 
glutamate receptor function and tumour biology, with 
knockdown of some non-GRIN2D glutamate receptor 
subunits resulting in both pro and anti-tumour effects 
[31]. Additionally increased serum levels of glutamate 
have been reported as a marker of malignant potential in 
prostate cancer [32], where it has also been observed to be 
positively related to advancing Gleason grade [33]. It has 
been proposed that this is due to glutamate acting to cause 
a genetic switch within the tumour, reducing the threshold 
for oncogenic k-ras signalling [34]. This is of particular 
relevance in colorectal cancer as mutations in the k-ras 
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oncogene is strongly implicated in the progression of 
colorectal cancer [35].
GRIN2D shows a promising tumour specific 
endothelial expression profile in a number of tumours, in 
particular colorectal cancer. However, it also appears to be 
expressed in a small subset of healthy tissues of the colon, 
stomach, esophagus and larynx as well as its reported 
expression throughout the brain and autonomic and 
enteric nervous systems [36]. The integrity of the blood 
brain barrier (BBB) and other nervous system protective 
structures must be ensured and maintained to avoid 
potentially serious side effects from GRIN2D guided 
Figure 4: GRIN2D-Fc vaccination decreases subcutaneous CT26 tumour growth and vascularity. CT26 tumour cells were 
inoculated into vaccinated and non-vaccinated Balb/c mice. A. tumour growth was monitored by caliper measurement. Tumours were excised at 
day 21, imaged, B. and weighed, C, D. representative H&E images of subcutaneous tumour morphology. E. quantitation from the H&E images 
of tumour vessel density. Statistical analysis for all, Mann-Whitney U, ***P<0.0001, **P<0.001.5 mice per group; 5 microscopic fields per tumour.
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therapies. If the BBB is intact the safety of immunological 
therapies should still be maintained, as large proteins 
like antibodies, cannot pass through the tight endothelial 
junctions of the BBB [37]. However, in 2-3% of cases of 
advanced CRC, patients develop brain metastases leading 
to disruption of the BBB [38]. This could make targeting 
GRIN2D potentially unwise in this setting. With this in 
mind, care will have to be taken in the selection of patients 
in which GRIN2D targeted therapies can be safely used.
Intriguingly GRIN2D expression in the vessels of 
colorectal cancer appears to be strongly associated, albeit 
not significantly so, with improved patient survival. The 
expression of tumour endothelial markers being associated 
with survival in this way is not without precedent. 
Expression of the tumour specific orphan receptor ELTD1 
has been reported to be associated with improved survival 
in head and neck, colorectal and ovarian cancers [39]. 
Increased expression of ROBO4, CLEC14A and ECSCR 
have also been associated with improvements in survival 
in non-small cell lung cancer [40]. It has been suggested 
that the expression of these pro-angiogenic TEMs could 
be associated with vascular normalisation within tumours. 
Indeed ROBO4-Slit2 signalling has been implicated in 
the normalisation of VEGF induced chaotic vascular 
structures [41]. This vascular normalisation could in turn 
lead to improved perfusion of the tumours leading to greater 
responsiveness to systematic blood-borne chemotherapeutics 
and therefore increased survival [39, 40].
Immune therapy is an established, yet still rapidly 
expanding field within anti-cancer therapy, with monoclonal 
antibody therapy forming the bulk of approved immune 
therapies in colorectal cancer. The field is constantly 
evolving, and novel applications have been described, 
including the use of a photosensitiser conjugated to 
an antibody specific to the Extra Domain B (EDB) of 
fibronectin, which demonstrated complete tumour ablation 
in a murine xenograft model of embryological tumour 
growth [42]. Other groups have focused on the generation 
of chimeric antigen receptor regulatory T-cells to selectively 
target the vasculature, for instance through the targeting of 
VEGFR2 in multiple murine cell lines, including the CT26 
line [43]. Work has been performed to this end in colitis-
associated colorectal cancer using CEA-specific Chimeric 
Antigen Receptor (CAR) regulatory T-cells [44].
Vaccination-based targeting of endothelial cell 
function, demonstrated for GRIN2D in this paper, offers 
certain benefits over these other novel approaches to 
tumour targeting, not least its potential for a relative lack 
of cost, due to the persistence of the immune response, 
and the avoidance of regular drug infusions. Having said 
this, research has shown that vaccination against a self-
antigen does not result in a persistent immune response, 
with circulating antibodies returning to baseline after 
seven months [45]. It is also important to note that for 
vaccination to be a successful strategy, it requires the 
host to possess an intact immune system. This is often 
compromised in patients with malignancy, either from 
their malignancy itself [46], or from the effects of 
exogenous steroids [47], chemotherapeutic agents [48], 
opioids [49] and even the emotional stress brought on 
by a cancer diagnosis and treatment [50]. Mechanisms 
are highly varied, but include T-cell mediated immunity, 
which may impact on the potential success of a pure 
vaccine-based treatment in this context.
In conclusion, GRIN2D is a promising vascular target 
in colorectal cancer for both treatment and prognostication. 
Endothelial function is impaired by siRNA-mediated 
disruption of gene function in in vitro angiogenesis assays 
and vascularisation is inhibited in in vivo models of normal 
and tumour angiogenesis. This effect may be due to reduced 
calcium flux within the endothelial cells, although this 
theory requires further investigation. The expression profile 
of GRIN2D throughout the body must be further assessed 
in order to ascertain the safety of systemic administration of 
GRIN2D targeted therapies.
MATERIALS AND METHODS
Quantitative reverse transcription polymerase 
chain reaction (RTqPCR)
RNA isolation and cDNA production was performed 
as previously described [51]. RTqPCR was performed 
using the Exiqon universal probe system (Roche, Burgess 
Hill, UK) as previously described [52]. Gene expression of 
samples was assessed in triplicate using the delta-delta CT 
method normalised to flotillin-2 unless otherwise stated. 
Primer sequences follow:
PECAM-1 Human
F: 5’-GCAACACAGTCCAGATA 
GTCGT-3’ 
R: 5’-GACCTCAAACTGGG 
CATCAT-3’
Flotilin-2 Human
F: 5’-GATCCTCAGCTTCAC 
CATCAA-3’
R: 5’-TCAGCATCTCTCTG 
CACCAC-3’
GRIN2D Human
F: 5’-GGCTCAGTGACCG 
CAAGT-3’
R: 5’-GCACGGTCCC 
AAACTTCA-3’
Immunohistochemical staining
Paraffin embedded sections were initially placed in 
xylene for 5 mins, then into 100% ethanol for 5 mins, then 
rehydrated by washing in water. Endogenous peroxidase 
block was performed using 0.3% hydrogen peroxide for 
15 mins. The slides were then washed with water, and 
antigen retrieval was performed by incubating overnight 
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in 1 mM EDTA pH 8.0 with 0.1% Tween in a beaker at 
65°C, with stirring overnight. The following day, the beaker 
was cooled with running water until at room temperature. 
The slides were then washed with PBS for 5 mins, and 
then were treated with 100 μl of 2x casein block. The 
slides were then incubated with 2 μg/ml mouse polyclonal 
antisera to CD31 (clone JC70, Dako, Ely, UK) or a custom 
antibody raised against the extracellular region of GRIN2D 
(Eurogentec, Southampton, UK) for 1 hour. The sections 
were then stained and visualized using the ImmPRESS 
universal antibody kit and ImmPACT NovaRed chromagen 
(Vector labs, Burlingame, CA, USA). The sections were 
counterstained with Mayer’s hematoxylin (Sigma), 
dehydrated and mounted in distyrene–plasticizer–xylene 
resin (Sigma). All images were acquired using a Leica 
DM6000 light microscope (Leica, Milton Keynes, UK). 
The following tissue arrays were used: MA2, MAN2, MC4, 
MCN4, CD4, CDN4, CDA3 (Superbiochip, Seoul, Korea).
siRNA knockdown of novel TEMs in HUVEC
Human umbilical cord vein endothelial cells 
(HUVEC) were isolated from human umbilical cords 
as previously described [53] and used at passage 2. 
1.75x105 HUVEC were plated into each well of a 6-well 
plate coated in 0.1% gelatine. These cells were incubated 
overnight at 37°C. A mix of 2.5 μl of 20 μM siRNA duplex 
and 167.5 μl Optimem (final duplex concentration of 50 
nM), and a mix of 3 μl RNAiMAX lipofectamine and 27 μl 
Optimem were incubated at room temperature for 10 mins. 
30 μl of lipofectamine mix was added to the duplex mix, 
flicked to combine, and incubated at RT for 10 mins. The 
seeded cells were then washed twice with PBS, and 800 
μl of Optimem was added. Then 200 μl of lipofectamine/
duplex mix was added to the cells, and incubated at 37°C 
for 4 hrs. At this stage, the media was aspirated off, and 
replaced with cM199 without antibiotics. The following 
day, the cells were harvested and assays performed.
Western blot
HUVEC were harvested by scraping, lysed, and 
subjected to 8% SDS-polyacrylamide gel electrophoresis. 
The protein was blotted onto nitrocellulose, stained with 0.3 
μg/ml rabbit polyclonal antisera to MCAM (HPA008848, 
Atlas Antibodies, Sigma), visualized with ECL peroxidase 
linked donkey anti–rabbit IgG (NA9340V, GE Healthcare) 
and ECL detection reagent (GE Healthcare) and used to 
develop Amersham Hyperfilm™ ECL (GE Healthcare).
Scratch wound assay
3x105 HUVEC were plated into each well of a 6-well 
plate and cultured in cDMEM at 37°C. Once the cells were 
confluent, a P200 pipette tip was used to make three parallel 
scratches both vertically and horizontally, resulting in 9 
intersections. The plate was then washed twice with PBS to 
remove any floating cells. Images were taken at 0 hrs, 6-8 
hrs and 16-24 hrs to measure wound closure.
Matrigel tube forming assay
A 1 ml aliquot of Matrigel was retrieved from the 
-80°C freezer, and allowed to defrost overnight in the 
cold room at 4°C and on ice. The following day, the wells 
of a 12-well plate were moistened with PBS, which was 
then removed to leave a thin film within the well. 70 μl 
of Matrigel was added to each well, and then allowed to 
solidify at 37°C for 30 mins. 1.4x105 cells were added to 
each well in 1 ml cM199. The assay was incubated for 16-
24 hrs, and then images acquired to measure tube number, 
length and branching.
Transwell filter assay (modified boyden chamber 
assay)
700 μl of 0.1% gelatine was added to each well 
of a 24-well plate, and then a cell permeable membrane 
was placed into the well, followed by a further 200 μl of 
gelatine. This was incubated at 37°C for 10 mins, then 
aspirated off. 700 μl of cM199 was added to the bottom 
of the well, with 3x104 HUVEC in low-serum M199 (1% 
FCS & no brain extract) placed on top of the filter. The 
assay was then incubated for 16-24 hrs.
Following incubation, the media was removed, and 
the wells washed with 700/200 μl of PBS. The PBS was 
then removed and replaced with equivalent volumes of 
fixing solution containing 2% Formaldehyde in PBS + 2 
μg/ml bisbenzamide for 15 mins. The fixing solution was 
then removed and the wells and filters washed with PBS.
To mount the filter, initially a drop of PBS was placed 
onto a slide, and then the filter was placed on top of this. 
A scalpel was used to excise the filter from its mounting, 
and the excess PBS wiped away. A drop of Shandon Immu-
Mount(TM was added to the filter, and a coverslip applied. 
The slides were then stored in the dark at 4°C until ready to 
be imaged. To quantify this assay, the slide was visualised 
at 20x magnification, and counts made of those cells atop 
and below the filter by adjustment of the focus. These scores 
from 5-10 sites on the slide were averaged, and the figures 
used to quantify percentage transmigration.
Generation of vector containing GRIN2D-GST 
fusion DNA
The insert DNA for the extracellular domain of 
GRIN2D was digested out of the GRIN2D-PIgG vector 
using the EcoR1 and BamH1 restriction sites using a double 
digestion, and ligated in a single reaction into the pGEX-
2T vector (GE Healthcare, Life Sciences, Little Chalfont, 
UK) using the same sites and T4 ligase. Following ligation, 
heat-shock transformation of ‘gold efficiency α-select’ cells 
was performed, followed by overnight culture on ampicillin 
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plates. Colonies were picked and grown up overnight, and 
then DNA extracted using the GeneJET Miniprep kit. 
These samples were sequence verified using the forward 
and reverse pGEX sequencing primers (GE Healthcare, Life 
Sciences, Little Chalfont, UK). The derived construct was 
scaled up by maxi-prep and stored at -20°C. This vector was 
named the pGEX2T-GRIN2D Vector.
Polyethylenimine (PEI) transfection of 
HEK293T cells
For a 15 cm plate, on the day before transfection 6x106 
HEK293T cells were plated out in 20 ml cDMEM. The 
following day, 18 μg of DNA was combined with 2 ml of 
Optimem serum-free media, and mixed by flicking of the tube. 
72 μg of PEI was then added and briefly vortexed at low speed 
to mix, followed by a 10 min incubation at room temperature. 
The mixture was then gently added to the HEK293T cells and 
mixed by north/south east/west movements.
Murine subcutaneous colorectal cancer model
Mice were handled and treated in accordance with 
home office requirements (Licence number, PPL. 40/3339). 
Balb/c mice were anaesthetised using inhaled Isofluorane, 
and following confirmation of depth of anaesthesia with 
a toe pinch, the left flank was shaved. Anaesthesia was 
maintained using a facemask. 1x105 Luciferase-transduced 
CT26 (CT26-Luc) colorectal cancer cells were injected 
into the left flank of each mouse. A one-week tumour 
establishment period was allowed, following which regular 
tumour calliper measurement was performed. This was 
combined with intraperitoneal injection of 200 μl of 15 mg/
ml D-Luciferin in PBS, and tumour growth measurement 
using the intravital imaging system (IVIS).
Murine subcutaneous sponge model
Buprenorphine was administered 1 hour prior to 
surgery. NSAIDs were avoided due to potential confounding 
effects on angiogenesis. Balb/c mice were anaesthetised using 
inhaled Isofluorane, and following confirmation of depth of 
anaesthesia with a toe pinch, both flanks were shaved. The 
skin was cleansed with ethanol. A small incision was made 
in the flank and a subcutaneous pocket created by blunt 
dissection. A 0.5 x 1.0 cm cylindrical sponge was inserted 
into the sub-cutaneous pocket and the skin closed using 6/0 
absorbable subcuticular sutures. This was then repeated for 
the other flank. Over the next 14 days, 100 μl of 20 ng/ml 
bFGF was injected into the sponge a total of 7 times, with 
a minimum of 12 hrs between injections. Animals were 
culled by a schedule 1 method, and the sponges fixed in 4% 
formalin prior to histological analysis.
Murine vaccination model
Balb/c mice were anaesthetised using inhaled 
Isofluorane, and following confirmation of depth of 
anaesthesia with a toe pinch, 100μl Freund’s Complete 
Adjuvant was injected subcutaneously with 50μg of either 
treatment or control protein. After 14 days, 100μl Freund’s 
Incomplete Adjuvant was injected subcutaneously with 
50μg of either treatment or control protein to boost the host 
antibody response. Tail vein bleeds were performed at days 
0, 14 and 28, with antibody response quantified by ELISA.
Enzyme-Linked immunosorbent assays (ELISA)
A Nunc Maxi-Sorp™ ELISA plate (eBioscience, 
Hatfield, UK) was coated with 100 μl of 2 μg/ml of GRIN2D-
GST or Fc protein, and incubated overnight at 4°C. The plate 
was blocked using 200 μl 3% BSA in PBS-T for at least 2 hrs. 
The plate was then washed 5 times with 100 μl PBS-T, and 
then 5 μl of serum in 45 μl PBS was incubated overnight in 
each well at 4°C. The following day, the serum was removed, 
and the plate washed 5 times. For antibody isotyping, 100 
μl of primary antibodies at 1 in 500 were incubated for 
90 mins. The plate was then washed 5 times. Peroxidase-
conjugated anti-mouse IgG (Dako, Ely, UK) was then applied 
as a secondary for 90 mins. For Ig Isotyping, IgG1, IgG2a, 
IgG2b, IgG3, IgM antibody (Sigma, Gillingham, UK) was 
applied as a secondary, then visualised using rabbit anti-goat-
HRP antibody (Dako, Ely, UK). The plate was incubated for 
15 mins in detection solution (10 mg o-phenylenediamine 
dihydrochloride (OPD) in sodium perborate/phosphate citrate 
buffer), and then quenched with 50 μl 3M HCl. Imaging was 
performed using a plate reader at 490 nm.
Vascular quantification
Following excision and formalin fixing of either 
sponges or tumours, specimens were paraffin embedded and 
mounted as 10μm sections. These then underwent staining 
with haematoxylin and eosin, and blood vessels counted in 
5 random fields per sample at 10x magnification.
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